Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
Weill Medical College of Cornell University
IGM Biosciences, Inc.
Vanderbilt-Ingram Cancer Center
AbbVie
OHSU Knight Cancer Institute
Melbourne Health
AbbVie
Calithera Biosciences, Inc
AbbVie
Weill Medical College of Cornell University
Swiss Cancer Institute
AbbVie
AbbVie
AbbVie
AbbVie
AbbVie
AbbVie
AbbVie
AbbVie